Analyst Ratings For Intra-Cellular Therapies (NASDAQ:ITCI)
Today, JPMorgan Chase & Co. initiated coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight with a price target of $25.00.
Some recent analyst ratings include
- 2/26/2018-JPMorgan Chase & Co. initiated coverage with a Overweight rating.
- 2/8/2018-Royal Bank of Canada initiated coverage with a Outperform rating.
- 12/15/2017-Canaccord Genuity initiated coverage with a Buy rating.
- 11/8/2017-SunTrust Banks Upgrade from a “Hold ” rating to a ” Buy” rating.
- 9/8/2017-BTIG Research Reiterated Rating of Buy.
- 9/8/2017-Cowen Reiterated Rating of Outperform.
- 9/7/2017-Piper Jaffray Companies Upgrade from a “Neutral ” rating to a ” Overweight” rating.
Recent Insider Trading Activity For Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies (NASDAQ:ITCI) has insider ownership of 21.00% and institutional ownership of 76.93%.
- On 2/16/2018 Lawrence J Hineline, VP, sold 49,700 with an average share price of $20.02 per share and the total transaction amounting to $994,994.00.
- On 1/22/2018 Michael Halstead, SVP, sold 25,500 with an average share price of $18.03 per share and the total transaction amounting to $459,765.00.
- On 1/8/2018 Kimberly E Vanover, SVP, sold 772 with an average share price of $17.46 per share and the total transaction amounting to $13,479.12.
- On 1/8/2018 Sharon Mates, Chairman, sold 6,604 with an average share price of $17.48 per share and the total transaction amounting to $115,437.92.
- On 1/5/2018 Kimberly E Vanover, SVP, sold 1,185 with an average share price of $17.37 per share and the total transaction amounting to $20,583.45.
- On 1/5/2018 Sharon Mates, Chairman, sold 11,257 with an average share price of $17.08 per share and the total transaction amounting to $192,269.56.
- On 1/4/2018 Lawrence J Hineline, CFO, sold 3,192 with an average share price of $15.67 per share and the total transaction amounting to $50,018.64.
Recent Trading Activity for Intra-Cellular Therapies (NASDAQ:ITCI)
Shares of Intra-Cellular Therapies closed the previous trading session at 20.23 up +0.77 3.96% with 20.0 shares trading hands.